| Literature DB >> 34531438 |
Madhuri Amulya Koduri1,2,3, Deeksha Prasad1,2,3, Shriya Upadhyaya1, Jilu Jaffet1,2,3, Swapna S Shanbhag1, Sayan Basu4,5, Vivek Singh6,7.
Abstract
To investigate the differential expression of tear cytokine levels among chronic Stevens-Johnson syndrome (SJS) patients to better understand the role of significantly altered cytokines in disease development. Tear samples were collected using Schirmer strips in 24 eyes of chronic SJS, 24 eyes of age and gender-matched controls, and 14 eyes of aqueous deficiency dry eye disease (DED) patients. The cytokine analysis was performed among 18 analytes which include pro-inflammatory, anti-inflammatory factors, and ELR-negative CXC chemokines. String analysis was performed for the significantly altered cytokines to understand their co-expression and role in the disease development. Additionally, a literature review was conducted to identify the signature cytokines present in chronic SJS tears. The differential expression of IL-6 (p ≤ 0.029), CXCL8/IL-8 (p ≤ 0.009), IL-1β (p ≤ 0.041), IL-2 (p ≤ 0.025), IL-10 (p ≤ 0.053), and CXCL-10 (p ≤ 0.044) were observed in chronic SJS patients and healthy controls. Whereas, IL-6 (p ≤ 0.029), CXCL8/IL-8 (p ≤ 0.058), CCL4 (p ≤ 0.056), GM-CSF (p ≤ 0.0001) IL-10 (p ≤ 0.025), and CXCL-10 (p ≤ 0.010), were differentially expressed in SJS as compared to severe DED patients. String analysis of the significantly altered cytokines revealed the involvement of several biological processes including the chronic inflammatory response, nitric oxide synthesis, angiogenesis, and cellular response to drugs. Among all the cytokines evaluated, the expression of CXCL8/IL-8 and CXCL10 levels were consistently reported in the literature. There was a differential expression of tear cytokines in SJS when compared to DED and healthy controls. The differential expression of CXCL8/IL-8 and CXCL10 was in line with existing literature and their role in chronic SJS pathogenesis merits further evaluation.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34531438 PMCID: PMC8446064 DOI: 10.1038/s41598-021-97575-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Ocular characteristics in eyes with chronic Stevens–Johnson syndrome. (A) Lid margin keratinization with tarsal conjunctival scarring in the upper eyelid (patient 11); (B) Upper lid post lid margin mucous membrane graft (patient 9); (C) peripheral corneal vascularization (patient 11); (D) Corneal scarring with vascularization with peripheral limbal vascularization (patient 9).
The table below shows the age and gender of chronic SJS, healthy controls and severe DED patients. Also the schirmer value and total protein concentration of the collected tears. Also the schirmer value and total protein concentration of the collected tears.
| Subjects | Age | Gender | Schirmer value OD:OS | Schirmer time (in min) | Total protein concentration |
|---|---|---|---|---|---|
| Controls | 30.8 ± 10.34 | 5:7 | 29.3 ± 1.48: 24.9 ± 7.52 | 3.92 ± 0.96 | 3252.6 ± 2444.55 |
| SJS | 32.25 ± 12.12 | 5:7 | 8.58 ± 4.52: 9.66 ± 3.86 | 5 | 1540.13 ± 972.97 |
| Severe DED | 43.5 ± 12.73 | 5:2 | 4.2 ± 0.76: 4 ± 0.81 | 5 | 1866.31 ± 858.57 |
Clinical characteristics of patients involved in this study with the slit lamp examinations of each of a patient.
| SJS Patients | Age (in years) | Gender | Duration since onset of disease | Drug sensitivity for | Significant ocular findings examined on slit lamp | COCS grade | |||
|---|---|---|---|---|---|---|---|---|---|
| Eyelids and eyelid margin | Conjunctiva | Cornea | |||||||
| Patient 1 | 26 | F | 11Y | Cefixime | RE | Few blocked orifices, thickened lid margins | Hyperemia | Scarring with 360 degree vascularisation | 16 |
| LE | Few blocked orifices, thickened lid margins | Hyperemia | Scarring with 360 degree vascularisation | 15 | |||||
| Patient 2 | 22 | M | 12Y | Paracetamol | RE | Thickened lid margins, symblepharon at medial canthus | Hyperemia | Superficial punctate keratopathy | 6 |
| LE | Thickened lid margins, symblepharon at medial canthus | Hyperemia | Superficial punctate keratopathy | 6 | |||||
| Patient 3 | 30 | M | 1Y/2 M | Sulphonamide | RE | Thickened lid margins, loss of eyelashes | Hyperemia, cicatrization | Vascularization with pannus | 27 |
| LE | Thickened lid margins, loss of eyelashes | Hyperemia, cicatrization | Vascularization with pannus | 26 | |||||
| Patient 4 | 34 | M | 7 M | antibiotics | RE | Lid margin mucous membrane graft | Normal | Superficial punctate keratopathy | 11 |
| LE | Lid margin mucous membrane graft | Hyperemia | Superficial punctate keratopathy | 13 | |||||
| Patient 5 | 23 | F | 10Y | Sulphonamide | RE | Lid margin keratinization | Normal | Vascularization | 13 |
| LE | Lid margin keratinization | Normal | Vascularization | 16 | |||||
| Patient 6 | 44 | M | 10Y | Sulphonamide | RE | Thickened lid margins, loss of eyelashes | Mild hyperemia | Scarring, superficial vascularization | 13 |
| LE | Thickened lid margins, loss of eyelashes | Mild hyperemia | Scarring, superficial vascularization | 13 | |||||
| Patient 7 | 60 | M | 12Y | Sulphonamide | RE | Lid margin keratinization | Hyperemia | Scarring, vascularization, conjunctivalisation | 27 |
| LE | Lid margin keratinization | Hyperemia | Scarring, vascularization, conjunctivalisation | 26 | |||||
| Patient 8 | 24 | F | 6Y | NA | RE | Lid margin keratinization | Superior symblepharon | Scarring, vascularization | 34 |
| LE | Lid margin keratinization | Superior symblepharon | Scarring, vascularization | 35 | |||||
| Patient 9 | 37 | F | 2Y | Penicillin | RE | Lid margin mucous membrane graft | Hyperemia | Scarring with vascualrization | 11 |
| LE | Lid margin mucous membrane graft | Hyperemia | Scarring | 23 | |||||
| Patient 10 | 19 | M | 2Y | Sulphonamide | RE | Distichiatic lashes | Hyperemia | Superficial corneal vascularization | 17 |
| LE | Distichiatic lashes | Hyperemia | Superficial corneal vascularization | 18 | |||||
| Patient 11 | 44 | F | 7Y | Cephalosporin | RE | Lid margin keratinization | Hyperemia | Superficial punctate keratopathy, peripheral corneal vascularization | 15 |
| LE | Thickened eyelid margins, loss of eyelashes | Hyperemia | Superficial punctate keratopathy, peripheral corneal vascularization | 13 | |||||
| Patient 12 | 24 | M | 5Y | NA | Lid margin mucous membrane graft | Hyperemia | Peripheral corneal vascularization | 11 | |
| Lid margin mucous membrane graft | Hyperemia | Peripheral corneal vascularization | 11 | ||||||
In Gender, F female, M male; in duration since onset of disease, Y years, M months; Ocular complications examined on slit lamp, RE right eye and LE left eye, COCS chronic ocular surface complication score [Score as given in Sotozono et al.[26]].
Figure 2Above figure shows the cytokine analysis in tear samples using multiplex ELISA. The expression of cytokines in chronic SJS tears are compared with the controls and severe DED tears. *p value ≤ 0.05, **p value ≤ 0.01, ***p value ≤ 0.001.
Figure 3Above data was generated using String software analysis from the existing literature. The figure illustrates the co-expression of the cytokines in normal homeostatic conditions which are reported in this study, where it is found that CXCL10 and CXCL9 are highly co-expressive (RNA co-expression score 0.848). And the next highest co-expressive chemokines are CXCL8/IL-8 and IL-6 which are pro inflammatory cytokines (RNA co-expression score 0.581). The results obtained in the current study reveals that the co-expression of CXCL10 and CXCL9 was lost in chronic SJS patient tear.
Figure 4The above figure shows the protein–protein interactions and its network statistics of the significantly altered cytokines in the current study, among chronic SJS patients when compared with normal and the cytokines involved in specific biological processes are detailed in Table 3.
This table illustrates the significantly altered cytokines and the biological processes which correlates with the clinical ocular condition of chronic SJS patients.
| GO term | Biological process | Cytokines involved | |
|---|---|---|---|
| GO:0002874 | Regulation of chronic inflammatory response to antigenic stimulus | IL-10, TNF | 1.55e−05 |
| GO:0045428 | Regulation of nitric oxide biosynthetic process | IFNG, IL-1B, 10, TNF | 1.97e−07 |
| GO:0035690 | Cellular response to drug | IL-1B, 6, TNF | 0.0011 |
| GO:0045765 | Regulation of angiogenesis | IL-1B, 6, 8, 10, CXCL10 | 1.00e−06 |
| GO:0050900 | Leukocyte migration | IL-1B, 6, 8, 10, TNF, CXCL9, CXCL10 | 1.46e−09 |
| GO:0006952 | Defense response | IL-1B, 6, 8, 10, IFNG, TNF, CXCL9, CXCL10 | 7.65e−08 |
| GO:0022603 | Regulation of anatomical structure morphogenesis | IL-1B, 6, 8, 10, TNF, CXCL9, CXCL10 | 4.11e−07 |
| GO:0042981 | Regulation of apoptotic process | IL-1B, 2, 6, 10, TNF, IFNG | 8.62e−05 |
Summary of differentially regulated inflammatory factors (pro-inflammatory and anti-inflammatory, ELR-negative CXC chemokines) comparing with severe DED and other previously existing studies among Stevens Johnson syndrome compared with age and gender matched controls of respective studies.
| Significantly altered analytes | Our study | Significance of analytes in SJS compared with healthy controls | |||
|---|---|---|---|---|---|
| Comparision with healthy controls | Comparision with severe DED | Gurumurthy et al. | Ueta et al. | Yoshikawa et al. | |
| IL-1a | – | – | – | – | ↑ |
| IL-1b | ↑ | ns | ↑↑↑ | – | – |
| IL-2 | ↑ | ns | ↑↑ | – | – |
| IL-6 | ↑↑ | ↑ | – | ↑↑↑ | ↑ |
| CXCL8/IL-8 | ↑↑ | ns | ↑↑ | ↑↑ | ↑↑ |
| IL-15 | ns | ns | ↑ | – | – |
| IL-17A | ns | ns | ↑↑↑ | – | – |
| TNF-alpha | ns | ns | ↓↓↓ | – | ns |
| IFN- γ | ns | ns | ↓↓↓ | ↑↑ | ns |
| Bfgf | ns | ns | ↑↑↑ | – | ns |
| RANTES/CCL5 | ns | ns | ↓↓ | ↑ | ns |
| MCP-1/CCL2 | ns | ns | ↑↑↑ | ns | ns |
| GMCSF | ns | ↓↓↓ | ↑↑↑ | – | – |
| GranzymeB | – | – | – | – | ↑ |
| Eotaxin | ↑↑ | ↑ | |||
| MIP-1b/CCL4 | ns | ns | ↑↑ | ↑ | |
| CD178 | – | – | – | – | ns |
| VEGF | – | – | ↓↓↓ | – | – |
| IL-12p70 | – | – | ↓↓↓ | – | – |
| IL-7 | – | – | ↓↓↓ | – | – |
| IL-10 | ns | ↓ | ↓↓↓ | – | – |
| IL-13 | – | – | ↓↓↓ | – | ns |
| CXCL10/IP-10 | ↓ | ↓↓ | ↓↓↓ | ↓↓ | ↓ |
| CXCL9 | ns | ns | – | – | – |
ns non-significant, ‘–’ is not studied.
↑—p value ≤ 0.05, ↑↑—p value ≤ 0.01, ↑↑↑—p value ≤ 0.001.